WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.084
Volume 12, Issue 20, 969-983. Review Article ISSN 2277–7105

NEUROLOGICAL COMPLICATIONS FOLLOWING HEART TRANSPLANTATION: INCIDENCES AND IMPLICATIONS

Peravali Jahnavi[1*], Nandini Yejarla[2], Maganti Tanuja[3], Kondru Vamsi[4], Sai Krishna Killa[5], Banavathu Karthik[6], Pradeep Chopra Gummadilli[7], Dr. Apada Reddy Gangadasu[8] and Dr. B. Thangabalan[9]

[1*,2,3,4,5,6,7,8,9]SIMS College of Pharmacy, Guntur, Andhra Pradesh – 522001, India.

Article Received on
30 September 2023,

Revised on 21 Oct. 2023,
Accepted on 10 Nov. 2023

DOI: 10.20959/wjpr202320-30317

***Corresponding Author**
Peravali Jahnavi
SIMS College of Pharmacy, Guntur, Andhra Pradesh – 522001, India.

ABSTRACT

The occurrence of neurological problems following heart transplantation is a complex and diverse challenge, exhibiting varying frequencies and consequences for patient well-being. This review presents a synthesis of the reported data about the occurrence and characteristics of these problems. Cerebrovascular events, such as stroke and transient ischemic episodes (TIA), have a wide range of incidence rates, spanning from 2% to 66.6%. This wide range underscores their significance as prominent problems. The broad spectrum of outcomes can be attributed to the possible impact of several factors, such as the diversity of patient demographics, changes in surgery and postoperative treatment, and differences in diagnostic criteria. Seizures, which have been reported to occur in up to 57.89% of cases, serve as a notable illustration of the range of postoperative neurological hazards. Several variables, including pre-existing medical problems and differences in perioperative therapy, will likely influence these risks. Intracranial bleeding, albeit less prevalent, with an incidence rate of up to 13.6%, presents a significant and potentially life-threatening danger. This underscores the importance of implementing careful and precise treatment strategies for anticoagulation. The prevalence of drug toxicity, which stands at 22.7%, highlights the intricate nature of treatment regimens following transplantation and the critical importance of diligent monitoring. Progressive multifocal leukoencephalopathy (PML)/encephalopathy, albeit less familiar with an incidence rate of 27.3%, refers to a severe illness that is frequently linked with immunosuppression. Delirium and meningitis, although infrequently reported at rates of 3% and 1.2%, respectively, continue to be critical postoperative issues due to their substantial impact on

morbidity. The results confirm that there is a high occurrence of diverse neurological problems following heart transplantation. This highlights the need for thorough monitoring, proactive treatment, and coordination among many disciplines to enhance patient care and prognosis.

KEYWORDS: - Heart transplantation, Neurological complications, Neurological incidence, post-heart transplantation complications.

INTRODUCTION

A cardiac transplant, which is often referred to as heart transplant surgery, is a surgical procedure performed on individuals who are experiencing terminal heart failure or severe coronary artery disease. This intervention is generally considered after alternative therapy options are futile. In contemporary medical practice, the prevailing approach entails the transplantation of a viable heart, occasionally accompanied by the lungs, from a recently dead donor to the recipient. This procedure has been widely used as of the year 2018. During the orthotopic operation, the patient's heart is either removed and replaced with the donor's heart, or in rare cases, the failing heart is preserved to provide support to the newly transplanted heart.

Every year, the United States performs almost half of the approximately 3,500 heart transplants undertaken globally. On average, patients of these heart transplants have a post-surgery life expectancy of 15 years. Although heart transplants do not provide a definitive cure for cardiac disease, they serve as a life-sustaining intervention that seeks to improve the overall well-being of individuals who receive them. Neurological problems are frequently observed after solid organ transplantation, manifesting in around one-third of individuals who have undergone heart transplantation, with reported incidence rates varying between 10% and 59%. These difficulties may occur due to the adverse effects of immunosuppressive medicines or their toxicities. Various post-heart transplant complications may arise, such as tremors, seizures, strokes, central nervous system infections, encephalopathy, and malignancies, which are potentially associated with the use of immunosuppressive medications. Pre-existing illnesses like past strokes or comorbidities, including diabetes, hypertension, and factors predisposing individuals to blood clot formation, may potentially enhance the susceptibility to neurological complications following transplantation. Neurological problems are identified as the leading cause of mortality in 20% of those who have had transplantation procedures.

Neurological complications, namely cerebrovascular disorders, have a higher incidence rate after heart transplantation compared to conventional cardiac procedures such as coronary artery bypass grafting. Ischemic stroke is the prevailing condition among these pathologies, while hemorrhagic stroke is less frequently observed. Hemorrhagic strokes may manifest in the early postoperative period as a result of a transition from diminished cardiac output before the transplantation procedure to enhanced perfusion afterward, in conjunction with compromised cerebral autoregulation. In contrast to many postoperative illnesses, such as delirium, peripheral nerve or muscle abnormalities, and seizures, which do not exhibit a significant association with increased mortality, the occurrence of a perioperative stroke is indicative of a heightened likelihood of dying within the initial year. Infections affecting the central nervous system following a transplant procedure are few in their occurrence during the early stages. However, when such infections do manifest, they frequently serve as an indicator of an unfavorable prognosis.

Neurological problems have the potential to impact around 50% of pediatric patients who have heart transplantation. Seizures that occur after transplantation frequently arise due to several factors, including the toxic effects of immunosuppressive drugs, imbalances in electrolyte levels or osmolality, central nervous system infections, cerebrovascular accidents, neoplasms, or pre-existing epileptic conditions. Seizures can be exhibited in two primary forms: partial or generalized. The most common presentation is tonic-clonic seizures, whereas nonconvulsive seizures are less frequent. Typically, seizures occur as isolated episodes and do not need continuous therapy. To examine seizures, medical assessments may encompass electroencephalography (EEG), computed tomography (CT) scans of the head, magnetic resonance imaging (MRI) scans, analysis of blood chemistry to assess levels of components such as magnesium, salt, and glucose, and, if symptoms indicate the possibility of meningitis, a lumbar puncture may be conducted.

Ischemic strokes and transient ischemic attacks, with a reported incidence of up to 13%, are often observed cerebrovascular events following heart transplantation. Conversely, cerebral hemorrhages, accounting for a mere 2.5% of cases, are considered a less prevalent etiology of stroke in this context.

Literature review

Neurological complications play a significant role in the morbidity and mortality experienced by individuals who undergo heart transplantation. The introduction of novel

immunomodulating agents has contributed to improved survival rates; however, it is worth noting that some of these agents have been linked to a higher incidence of neurological complications, both infectious and non-infectious. In this particular study, the researchers aimed to assess the frequency of neurological complications in heart transplant recipients both before and after the implementation of daclizumab induction therapy. It was found that non-infectious complications accounted for most (68%) of the episodes of neurological complications, while infectious complications comprised the remaining 32%. The incidence of non-infectious complications was 15.1% in the OKT3-ATG group and 7.3% in the daclizumab group. On the other hand, the incidence of infectious complications was 7.5% in the OKT3-ATG group and 1.4% in the daclizumab group. Nevertheless, these complications still affect many recipients, ranging from 14% to 48%.[1]

The paper examines the technical considerations in reducing neurological complications following cardiac transplantation. The study emphasizes the precise everting atrial and great vessel anastomoses utilized in the surgical technique, as well as the modified order of anastomoses. The study reveals that the incidence of early and late neurological complications after transplantation was each below 2%. Moreover, the continuous intraarterial irrigation of the left heart during graft implantation can aid in evacuating left-sided air and reduce the risk of air embolism. Notably, the study did not observe any air embolism in their series. Ultimately, the paper underscores the significance of technical modifications and meticulous de-airing techniques in reducing neurological complications following cardiac transplantation.[2]

Neurologic complications may arise after heart transplantation, necessitating a comprehensive assessment during the heart transplant evaluation to identify any potential peripheral nervous system ailments. Among patients referred for heart transplant evaluation, the most frequently encountered peripheral neurologic disorder is peripheral neuropathy, often associated with diabetes. Following heart transplantation, patients may manifest symptoms such as altered levels of consciousness, impaired vision, tremor, myoclonus, chorea, and seizures. In patients experiencing neurologic symptoms post-heart transplantation, the electroencephalogram (EEG) typically exhibits widespread slowing. Notably, the administration of steroids in heart transplant patients can engender behavioral disorders, which may be further aggravated by underlying metabolic irregularities. The

therapeutic approach entails reducing or discontinuing intravenous steroid usage and correcting the underlying metabolic abnormalities.[3]

This study represents the inaugural attempt to prospectively contrast the morbidity of the nervous system following heart transplantation in patients afflicted with Chagas' disease and those without said affliction. The study assessed the neurological and neuropsychological outcomes in patients with Chagas' disease and those without the disease who were suffering from severe cardiac failure, both before and after the transplantation procedure. The study specifically excluded patients presenting with concurrent infection, neoplasms, renal, hepatic, or pulmonary failure, pulmonary hypertension, dementia, or psychiatric disorders. Neurological examinations were administered at six-month intervals post-surgery and in the event of any neurological occurrences, with subsequent changes being analyzed about the preoperative examination.[4]

Neuropsychological investigation regarding individuals awaiting heart transplants has not kept pace with other areas of interest, such as dementia and stroke. Cardiac procedures or neurological co-morbidities cannot entirely account for the cognitive deficiencies observed in this group. Subsequent research endeavors will probe the correlation between specific cardiac functions and cognition, the enduring impact of cardiac events on brain function, and the potential for cognitive deficits to be reversed through interventions such as heart transplantation. The study divulged that heart transplant candidates, regardless of age, commonly exhibited significant cognitive impairments, irrespective of the presence of neurological co-morbidities. Furthermore, neurological co-morbidities, including cerebrovascular accidents and cardiac arrest, were frequently encountered in heart transplant candidates and were associated with lower scores on measures of processing speed, memory, and executive functioning. On the whole, existing literature suggests that heart transplant candidates endure cognitive impairments that cardiac procedures or neurological co-morbidities cannot fully explain.[5]

Neurological complications, such as cerebrovascular complications, are a significant cause of illness and death in patients who undergo orthotopic heart transplantation. During the perioperative period, cerebrovascular complications occur in 5-11% of heart transplant patients, with ischemic stroke being the most prevalent subtype. Risk factors for perioperative cerebrovascular complications include unstable blood flow, cardiac arrest, prolonged use of extracorporeal circulation, previous history of stroke, and carotid stenosis greater than 50%.

Cerebrovascular complications are associated with increased mortality and unfavorable functional outcomes at one-year follow-up. Following the perioperative period, the only significant risk factor for cerebrovascular complications is a previous history of stroke, whether ischemic or hemorrhagic. Long-term follow-up studies indicate that up to 72% of heart transplant recipients may encounter neurological complications, with an 8% mortality rate in the initial year. Ventricular assist devices and cardiac catheterization are additional risk factors for cerebrovascular events in heart transplant patients.[6]

Neurological complications manifest in 50% to 70% of patients after heart transplantation, predominantly during the perioperative phase. The most prevalent neurological complication after the postoperative period is ischemic stroke, succeeded by neurotoxicity. Diabetes and chronic renal failure serve as risk factors for the incidence of seizures after heart transplantation. Neurological complications manifest in 50% to 70% of patients undergoing heart transplantation and are the leading cause of mortality in 20% of patients. A clinical series determined that cerebrovascular complications developed in roughly 9% of transplant patients, with half of the cases directly associated with the surgical procedure, monitoring, or treatment.[7]

The rapid availability of heart transplantation should be considered a viable alternative for several people suffering from fatal cardiac illness. The authors conducted a comprehensive analysis of relevant clinical factors recorded in a database comprising 137 patients who had orthotopic cardiac transplantation from June 1988 to February 1998. The researchers ascertained the pattern, classification, and magnitude of neurologic problems occurring during or after the surgical procedure. The study encompassed a comprehensive analysis of neuroimaging findings, examining autopsy data. The Cox proportional hazards model was utilized to do multivariate analysis. The Kaplan-Meier method was employed to create survival curves. A total of 137 patients were included in the study, with 106 (77%) identified as male and 31 (22%) identified as female. The age range of the participants ranged from 1 to 70 years. The Kaplan-Meier analysis revealed that the one-year survival rate was 94%, while the five-year survival rate was 62.0%. Additionally, the study found that the survival rate after one year was 86.1%. During the study, a cohort of 25 individuals (comprising 18% of the total sample) had neurologic problems. The average length of follow-up for these patients was 9.6 years. 48% of the observed neurologic problems manifested within the initial 14-day

period following surgery, while a significant majority of 80% were observed within the first 60 days post-surgery.[8]

Following the pioneering human heart transplantation performed by Barnard in 1967, there was initially a surge of enthusiasm for this procedure. However, over time, the utilization of cardiac transplantation declined due to the growing recognition of challenges associated with patient selection, graft rejection, and low rates of survival. During the period spanning from 1984 to 1989, a total of 90 individuals had orthotopic cardiac transplantations as a treatment for end-stage, refractory congestive cardiomyopathy. The study sample consisted of 75 male and 15 female patients, ranging in age from 10 to 65 years, with a mean age of 43.5 years. A total of six individuals, accounting for 7% of the sample, experienced acute neurologic episodes during the perioperative period. Three patients got cerebral infarction. A right parietal infarction took place ten days before transplantation following two instances of cardiac arrest and extended systemic hypotension, necessitating the use of ventricular support devices. The occurrence of cerebral infarction in the parieto-occipital area is likely attributed to cerebral hypoperfusion. Two other individuals experienced infarction after the transplanting procedure. The patient responded satisfactorily to exclusive antiplatelet medication, resulting in subsequent restoration of eyesight. Two patients experienced acute intracerebral bleeding for durations of 14 and 36 days, respectively, after transplantation. One of the occurrences was situated mainly in the putamen region, while the other occurred in the basal ganglia and subcortical regions. Both patients had intermittent episodes of severe hypertension, renal failure, sepsis, and coagulopathy. In one patient, the development of renal failure, sepsis, and coagulopathy preceded the occurrence of bleeding. Both of the three patients who experienced ischemic strokes achieved complete recovery, whereas the other patient continued to exhibit chronic dysphasia. The patient who underwent a toxic response to cyclosporine achieved full recovery by a gradual reduction in the dosage of the medicine.[9]

The neurologic assessment of a specific cardiac transplant patient frequently results in a diagnosis that cannot be made quickly at the bedside. Only a few clinical observations are reliable throughout time. An embolic cerebral infarction often brings on early post-operative seizures. However, seizures most frequently occur as a neurotoxic side effect of cyclosporine. Acute delirium and psychosis that begin in the first week following heart transplantation typically have numerous underlying causes and are treatable. An adequate electrophysiological test can confirm the presence of post-operative brachial plexopathy or

mono neuropathy, which can be treated. Phycomycosis is associated with the start of periorbital inflammation, ophthalmoplegia, nasal turbinate or sinus invasion, and necrosis. However, most patients report generalized symptoms of poor mentation with or without focal neurologic indications. These patients need a pretty extensive investigation for neurologic problems that might be manageable. An aggressive diagnostic approach, occasionally including a stereotaxic brain aspirate or biopsy, is indicated in a medically stable patient. Empirical therapy for the condition that is most likely to respond to treatment is appropriate in very ill patients with multiple organ failure.[10]

Despite successful transplantation, neurological problems in orthotopic heart transplantation are a significant cause of morbidity and mortality. Hemodynamic instability, cardiac arrest, extracorporeal circulation lasting more than two hours, a history of stroke, and carotid stenosis greater than 50% have all been identified as risk factors for the development of cerebrovascular problems during the perioperative period. Hyperperfusion syndrome is a cerebrovascular complication percentage of cerebrovascular problems occurred in the first two weeks following transplantation, according to a retrospective assessment of 314 patients who underwent heart transplantation, whereas 80% occurred in the late post-operative phase. The exact cardiac condition that necessitated a transplant and the cerebrovascular problems are not related.[11]

In orthotopic heart transplantation, neurologic problems are a significant cause of morbidity and mortality. In a prospective observational study, we sought to determine the frequency and course of neurologic problems following heart transplantation. All patients with end-stage cardiac failure were assessed by the same neurologist between September 1993 and September 1999 as part of our standard heart transplantation process before and at the time of any neurologic event (symptom or complaint) following the transplant. Out of 120 applicants who underwent evaluation, 62 underwent successful transplantation. Men; 45.5 years on average old; 26.8 months on average for follow-up). 15 patients (24%) were ischemic, 22 (2%) had congenital cardiomyopathy, 24 (39%) had Chagas disease, and (35%) were idiopathic. 19 Neurological patients (31%) experienced problems, including tremors, severe headache, temporary encephalopathy, and seizures. Spinal cord compression in 4, peripheral neuropathy in 3, and medication toxicity or metabolic abnormalities in 13 cases. (Epidural abscess and metastatic prostate cancer) in two. There were no signs of a postoperative stroke. Neurologic problems were common but seldom resulted in long-term impairment or death.

The reduced frequency of ischemic stroke in our dataset may be responsible for the lack of symptomatic stroke.[12]

Cerebrovascular problems following orthotopic heart transplantation (OHT) have a higher prevalence when contrasted with neurological sequelae after regular cardiac surgery. The occurrence of ischemic stroke and transient ischemic attack (TIA) is more prevalent, with an incidence rate of up to 13%, compared to cerebral bleeding, which has a lower incidence rate of 2.5%. From a clinical perspective, the presence of localized neurologic impairments is indicative of ischemic stroke. Nevertheless, on certain occasions, a stroke may present as a quiet event or exhibit itself through the emergence of encephalopathy, indicating a widespread cerebral dysfunction. The distribution of ischemic stroke subtypes throughout the perioperative and postoperative period following orthotopic heart transplantation (OHT) exhibits notable differences from the traditional distribution, indicating the presence of different pathogenic processes. Less common and uncommon pathways associated with surgical procedures and postoperative inflammation may contribute to the development of ischemic stroke, particularly in this specific patient population. Nevertheless, a significant proportion of strokes (40%) manifest without an identifiable cause, sometimes referred to as cryptogenic strokes. The potential involvement of silent atrial fibrillation (AF) in the development of these strokes, as well as the potential use of P wave dispersion as a predictor of AF, may be significant factors in the pathophysiology of these strokes. In individuals with occlusive cerebrovascular disease, a correlation exists between the dispersion of P waves and homocysteine levels in the plasma. The presence of elevated amounts of homocysteine, known as hyperhomocysteinemia, may contribute to the development of these strokes via many processes that increase the risk of atrial fibrillation. In summary, the occurrence of stroke following heart transplantation is a significant complication that has substantial implications not just for death rates but also for later unfavorable functional outcomes. In contrast to the occurrence of neurological complications after conventional cardiac surgery, cerebrovascular challenges are observed with greater frequency in the context of orthotopic heart transplantation (OHT). The occurrence of ischemic stroke and transient ischemic attack (TIA) is higher, with an incidence of up to 13%, compared to cerebral hemorrhage, which has a lower occurrence rate of 2.5%. The clinical manifestations of an ischemic stroke encompass the appearance of focal neurological impairments. Impairments resulting from a stroke, although they may occasionally go undiagnosed or manifest as encephalopathy, are indicative of a widespread cerebral dysfunction—the distribution of ischemic stroke subtypes observed

during surgical procedures. Additionally, the postoperative phase after orthotopic heart transplantation (OHT) exhibits distinct detrimental pathways that deviate from the conventional distribution. In actuality, ischemic stroke might also be influenced by less well-defined and infrequent mechanisms, such as those related to surgical interventions and atypical postoperative inflammation within this particular group of patients. Nevertheless, a significant proportion of strokes, around 40%, occur.[13]

Worldwide, millions of people suffer from heart failure. A range of 7-81% of cardiac transplants result in neurological problems. After heart transplantation, posterior reversible encephalopathy syndrome (PRES) is the most typical neurologic consequence. Based on age, gender, weight, and other demographics, as well as characteristics like the length of ICU stay, duration of mechanical ventilation, and intraoperative features, patients were separated into two groups. Three groups of patients with neurological issues are created: first month, between 1 and 6 months, and after six months. For group comparisons, the Student T-test and Mann-Whitney U test are utilized. Multiple logistic regression analysis is used to define risk for outcome. Thirty-three patients who underwent heart transplants were left out of the total of 130 patients.22 (23.7%) of the 97 heart transplant recipients experienced neurologic problems, with five (22.7%) of these patients placing first month between 1 and 6 months, there were six patients (27.3%), followed by 11 patients (50%) after six months. PRES (n=6,27.3%), calcineurin inhibitor toxicity (n=5,22.7%), intracranial hemorrhage (n=3,13.6%), seizures (n=2,9.2%), and stroke (n=2,9.2%) were the most frequent diagnoses, followed by femoral neuropathy (n=1,4.5%), myopathy (n=1,4.5%), phrenic nerve injury (n=1,4.5%), and cerebral abscess (n=1,4.5%). The most typical neurologic complication, or 27.3% of cases, is PRES. In males, the risk of neurologic complications is three times higher. Sepsis rates were noticeably more excellent in heart transplant recipients who experienced neurologic issues.[14]

Cardiac transplantation is a recognized treatment for patients with terminal heart disease in some circumstances. About 300 people worldwide have undergone the treatment since its launch in 1968 and possess cardiac homografts. Even though 50% of patients currently live procedures delayed by at least a year, postoperative issues remain a serious issue. Patients who had heart transplants have been shown to have a broad range of neurological problems. Occlusive and hemorrhagic cerebrovascular disease are two of these ailment, central nervous system infections, lymphoreticular cancer, multiple sclerosis, progressive multifocal

leukoencephalopathy, and central pontine myelinolysis, myopathy, peripheral neuropathy, and metabolic encephalopathy. Several of these instances are for CNS illnesses. Others have less evident underlying causes, possibly partially related to their presence. Suppose there is hypertension, uremia, electrolyte abnormalities, and general malnutrition. Similar in-depth data is not available from people who have had heart transplants. The neurological complications encountered in 83 patients who received cardiac homografts over seven years lead to Neurological disorders common in transplant recipients, occurring in over 50 percent of patients. Infection was the single most frequent cause of neurological dysfunction, being responsible for one-third of all CNS. According to 83 individuals who got cardiac homografts over seven years and experienced neurological issues, neurological abnormalities are common among transplant recipients, taking place in more than 50% of patients. Infections were the most common type of illness. Being accountable for one-third of all CNS dysfunction, the etiology of neurological impairment complications. The pathogenicity of the infectious species was generally rated as low: fungi, viruses, protozoa, and an unusual bacterial strain. Vascular lesions were linked to other clinical neurological disorders, frequently from cerebral infarction or ischemia that occurred during the surgical procedure, acute cerebral microglioma, and metabolic.[15]

RESULTS

Our study reviewed the examination of neurological problems following heart transplantation. We have found an array of symptoms that are frequently observed in patients who have undergone heart transplantation.

The incidence of stroke and transient ischemic attack (TIA) following transplantation varies significantly, with reported rates ranging from as low as 2% to as high as 66.6%. This suggests that cerebrovascular events pose a notable issue following heart transplantation, with potential variations attributable to variances in patient cohorts, surgical methodologies, postoperative management, and stroke/transient ischemic attack diagnostic criteria. Seizures are a documented neurological consequence, with reported incidence rates reaching up to 57.89%. The broad spectrum of patient risk factors, including pre-existing neurological disorders or variations in the perioperative care of transplant patients, indicates a significant level of variability.

Intracranial hemorrhage, a severe consequence, has been documented to occur at lower frequencies, with reported incidences reaching up to 13.6%. The observed diversity may be

ascribed to variations in the treatment of anticoagulation, demographic characteristics of patients, and the prevalence of hypertension or other risk factors among the populations under investigation.

Drug Toxicity: It is common for post-transplant individuals to be prescribed a combination of drugs, including immunosuppressants, which possess neurotoxic properties. The reported incidence of drug toxicity is up to 22.7%. This underscores the significance of meticulous drug administration and surveillance for neurotoxic adverse effects in this specific group of patients.

The incidence of Progressive Multifocal Leukoencephalopathy (PML) or encephalopathy following heart transplantation has been reported to be as high as 27.3%. This particular medical disease is relatively uncommon, yet it can manifest as a severe ailment and is frequently linked to a compromised immune system.

The incidence of delirium following transplantation has been reported to be as high as 3%. Delirium is a prevalent acute neuropsychiatric illness that may be correlated with the psychological strain induced by surgical procedures, hospitalization, and the highly demanding intensive care setting.

Meningitis is a condition that is seldom documented, with a prevalence rate of 1.2%. Post-transplant meningitis is a significant medical problem frequently linked to immunosuppression and susceptibility to infections.

In brief, it is not rare for heart transplant recipients to experience neurological problems, which can exhibit considerable variability in their frequency. Stroke and transient ischemic attack (TIA), as well as seizures, have been consistently identified as the most often occurring conditions in various research, suggesting that they are rather prevalent issues within this particular patient group. Additional disorders such as cerebral bleeding, medication toxicity, and PML/encephalopathy, although less commonly documented, present notable concerns following surgery that need careful observation and control. Delirium is an acknowledged consequence in the postoperative context but with less frequent mention, whereas meningitis is observed as an uncommon yet significant occurrence after heart transplantation.

DISCUSSION

The review indicates that individuals who have heart transplantation are at an increased risk for several neurological problems. The observed heterogeneity in reported incidence rates is presumed to be influenced by several factors, including but not limited to patient selection, perioperative care practices, immunosuppressive treatment protocols, and the specific criteria employed for defining and diagnosing these problems.

Stroke and transient ischemic episodes (TIA) are often seen as neurological disorders, exhibiting a significant variation in their occurrence rates. The observed diversity in this context may be attributed to the intricate interaction of many risk factors, including atrial fibrillation, systemic hypertension, and hypercoagulability, which may be further intensified during the transplantation procedure. The necessity for thorough neurological monitoring and preventative measures, such as improving hemodynamic control and cautious anticoagulation, is emphasized by the elevated occurrence rates observed in some cohorts.

Seizures represent a prevalent neurological complication following transplantation and can be triggered by a range of causes, including metabolic imbalances, infections, or the direct neurotoxic impacts of drugs. The considerable variation in the occurrence of seizures implies that certain groups of patients or treatment methods could be associated with a greater likelihood of experiencing seizures. This underscores the need to conduct personalized evaluations and perhaps consider preventive anticonvulsant medication for individuals at a higher risk.

Intracranial bleeding, although less prevalent compared to stroke or seizures, is a grave consequence that exerts a substantial influence on patient outcomes. The administration of anticoagulant therapy in heart transplant recipients is a significant challenge, as it necessitates a careful equilibrium between mitigating the danger of blood clot formation and averting bleeding problems.

The potential for drug toxicity to induce neurological problems is of significant concern, especially in the context of heart transplant recipients who require long-term immunosuppression. The drugs in question have been linked to neurotoxicity, which can present as a range of symptoms ranging from moderate disorientation to severe encephalopathy or even progressive multifocal leukoencephalopathy (PML). Unfortunately, therapeutic options for PML are limited, and the prognosis is generally poor. The available

data indicates that it is crucial to monitor medication levels and harmful adverse effects closely.

The incidence of delirium and meningitis, although relatively infrequent, are medical diseases that demand attention due to their capacity to result in substantial morbidity. The occurrence of delirium frequently presents as a complication in the postoperative period, serving as a potential marker for other underlying issues. Meningitis, although infrequent, is a significant concern within the immunocompromised demographic due to the substantial morbidity and death rates linked to infections affecting the central nervous system.

In summary, the existing body of data demonstrates that heart transplant patients have considerable neurological problems. The prevention and management of these issues necessitate using a multidisciplinary strategy. It is imperative to do regular neurological assessments, both before and after transplantation, and to maintain diligent surveillance. Additionally, additional investigation is required to elucidate the specific processes and risk factors linked to neurological difficulties in this demographic, facilitating the formulation of focused interventions and therapeutic approaches.

CONCLUSION

In conclusion, it is imperative to increase awareness and implement proactive care measures in response to the occurrence and severity of neurological problems following heart transplantation. Optimizing patient outcomes necessitates implementing a multidisciplinary strategy encompassing the collaboration of many medical professionals, such as cardiologists, neurologists, pharmacologists, and transplant surgeons. Ongoing investigation aimed at improving diagnostic criteria, strengthening surveillance efforts, and advancing the development of preventative and therapeutic measures is of utmost importance. The adoption of an integrated strategy is of paramount importance for addressing the intricate interaction of several variables that contribute to neurological problems and enhancing the overall well-being of individuals who have had heart transplantation.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

ACKNOWLEDGMENTS: The authors acknowledge, "This review received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors."

REFERENCES

1. Muñoz, Patricia MD, PhD; Valerio, Maricela MD; et al. Medicine, May 2010; 89(3): 166-175. DOI: 10.1097/MD.0b013e3181dfa59c.
2. Michael E. Jessen M.D., Dan M. Meyer M.D., et al. published, September 1993; https://doi.org/10.1111/j.1540-8191.1993.tb00411.x.
3. Alain Heroux 1, Salpy V. Pamboukian 2 et al, 21 December 2013, https://doi.org/10.1016/B978-0-7020-4088-7.00082-1.
4. S. M. F. Malheiros, A. A. Gabbai, et al. First published, 29 January 2009, https://doi.org/10.1111/j.1600-0404.1997.tb00278.x.
5. Roman DD, Holker EG, Missov E, Colvin MM, Menk J et al, 1: 118-137. Doi: 10.1080/13854046.2016.1212096. Epub 2016 Aug 5. PMID: 27491277.
6. Aída Alejaldre, Raquel Delgado-Mederos et al, 2010 Aug; 6(3): 214–217. doi: 10.2174/157340310791658811.
7. F. Pérez-Miralles b, J.C. Sánchez-Manso b, L. Almenar-Bonet a et al, https://doi.org/10.1016/j.transproceed.2005.09.162.
8. A.A Jarquin-Valdivia a, E.F.M Wijdicks a, C Mc Gregor a, https://doi.org/10.1016/S0041-1345(99)00294-8.
9. B. T. Andrews, J. J. Hershon, P. Calanchini, G. J. Avery, 2nd, and J. D. Hill West J Med, 1990 Aug; 153(2): 146–148., PMCID: PMC1002499PMID: 2219870.
10. John R. Hotson M.D. *, Dieter R. Enzmann M.D. Neurologic Clinics, 6(2): https://doi.org/10.1016/S0733-8619(18)30874-0.
11. Aída Alejaldre, Raquel Delgado-Mederos et al. Curr Cardiol Rev, 2010 Aug; 6(3): 214–217, doi: 10.2174/157340310791658811.
12. Arq. Neuro-Psiquiatr. 60(2A), June 2002, https://doi.org/10.1590/S0004282X2002000200002.
13. J Stroke, 2016 May; 18(2): 157–168. Published online 2016 Feb 26. doi: 10.5853/jos.2015.01599.
14. Cureus, 2021 Nov; 13(11): e19425. Published online 2021 Nov 10., doi: 10.7759/cureus.19425.
15. JOHN R. HOTSON, TIMOTHY A. PEDLEY Brain, December 1976; 99(4): 673–694, https://doi.org/10.1093/brain/99.4.673.